抗體藥物複合體(ADC)契約製造市場規模、佔有率和成長分析（按研發階段、製程組件、標靶適應症、抗體生成、抗體來源和地區分類）－2026-2033 年產業預測

全球抗體藥物複合體(ADC)契約製造市場規模預計在 2024 年達到 96.4 億美元，從 2025 年的 108.1 億美元成長到 2033 年的 269.5 億美元，在預測期（2026-2033 年）內複合年成長率為 12.1%。

全球抗體藥物複合體(ADC)契約製造市場正經歷顯著成長，這主要得益於對標靶癌症療法的需求不斷成長以及生物製藥研發的進步。癌症發生率的上升促使精準醫療成為重要的治療手段，而 ADC 也因此成為關鍵的治療手段。生技製藥和生技公司不斷增加研發投入，預計將進一步推動市場成長。此外，ADC 生產流程複雜，需要專業的生物偶聯技術和先進的檢測方法，這也創造了新的商機。同時，監管機構對創新 ADC 療法的支持（例如加速核准程序）預計將推動對契約製造服務的需求。然而，高昂的生產成本、嚴格的監管、專業生產商的匱乏以及供應鏈問題等挑戰可能會限制市場滲透率。

推動全球抗體藥物複合體契約製造市場發展的因素

抗體藥物複合體）治療應用範圍的不斷擴大，正促使眾多製藥和生技公司加強研發投入。隨著臨床試驗的推進，市場對能夠提供擴充性且符合規範的生產能力的製造合作夥伴的需求日益成長。此外，全球核准的抗體藥物複合體數量不斷增加，預計將為專注於此類創新治療方法契約製造的公司創造新的機會。這種動態情勢表明，外包生產服務對於滿足抗體藥物複合體市場不斷變化的需求至關重要。

限制全球抗體藥物複合體契約製造市場的因素

由於抗體藥物複合體）的設計、開發和生產流程複雜，全球契約製造市場面臨許多限制因素。此類生產需要專門的設施，包括抗體生產、細胞毒性藥物處理和偶聯工藝，因此需要大量的資本投入。此外，檢驗安全性和有效性所需的大量臨床前和臨床試驗導致研發高成本，這可能會在長期內抑制該領域對契約製造服務的需求。這些因素共同為市場相關人員帶來了巨大的挑戰。

全球抗體藥物複合體契約製造市場趨勢

全球抗體藥物複合體）契約製造市場正呈現出顯著趨勢，這主要得益於主要企業之間的策略聯盟和產能擴張。為了提高營運效率並降低供應鏈中斷的風險，各公司擴大與製藥創新者合作，以確保獲得專屬的生產資源，從而簡化生產流程。這種合作模式不僅有助於消除瓶頸，也凸顯了市場對靈活生產解決方案日益成長的需求。隨著醫療保健產業的不斷發展，擴充性和柔軟性日益受到重視，這一市場趨勢被視為持續成長的基礎，並有助於提供先進的治療藥物以滿足不斷成長的全球需求。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 原料分析

全球抗體藥物複合體（ADC）契約製造市場規模（按研發階段和複合年成長率分類）（2026-2033 年）

• 第一階段
• 第二階段
• 第三階段

全球抗體藥物複合體（ADC）契約製造市場規模（按生產流程和複合年成長率分類）（2026-2033 年）

• 抗體
• 高毒性強效藥物（HPAPI）/細胞毒性有效載荷
• 鍵/連接體
• 填充和精加工

全球抗體藥物複合體（ADC）契約製造市場規模（按目標適應症和複合年成長率分類）（2026-2033 年）

• 固態腫瘤
• 血液腫瘤
• 其他

全球抗體藥物複合體(ADC)契約製造市場規模（以抗體代數和複合年成長率分類）（2026-2033 年）

• 第二代
• 第三代
• 第四代
• 新一代

全球抗體藥物複合體(ADC)契約製造市場規模（按抗體來源和複合年成長率分類）（2026-2033 年）

• 人源化抗體
• 嵌合體體
• 小鼠衍生
• 其他

全球抗體藥物複合體(ADC)契約製造市場規模（按連接子類型和複合年成長率分類）（2026-2033 年）

• 馬來醯亞胺
• SMCC
• 四肽連接子
• 纈氨酸-瓜氨酸
• 其他

全球抗體藥物複合體（ADC）契約製造市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 製藥公司
• 生技公司 - 30%
• 學術和研究機構
• 其他

全球抗體藥物複合體（ADC）契約製造市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Lonza Group AG（Switzerland）
• WuXi XDC（China）
• Catalent, Inc.（USA）
• Piramal Pharma Solutions（India）
• MilliporeSigma（Germany）
• Sterling Pharma Solutions（UK）
• AGC Biologics（USA）
• Cerbios-Pharma SA（Switzerland）
• CARBOGEN AMCIS（Switzerland）
• Curia（USA）
• Abzena PLC（UK）
• WuXi Biologics（Cayman Islands）
• Ajinomoto Bio-Pharma Services（Japan）
• Axplora（France）
• Sartorius AG（Germany）
• Samsung Biologics（South Korea）
• Recipharm AB（Sweden）
• AbbVie Contract Manufacturing（USA）
• Formosa Laboratories（Taiwan）
• Veranova（USA）

結論與建議

Global Antibody Drug Conjugates Contract Manufacturing Market size was valued at USD 9.64 Billion in 2024 and is poised to grow from USD 10.81 Billion in 2025 to USD 26.95 Billion by 2033, growing at a CAGR of 12.1% during the forecast period (2026-2033).

The global market for antibody drug conjugates (ADCs) contract manufacturing is experiencing significant growth driven by the rising demand for targeted cancer therapies and advancements in biologics research and development. As cancer prevalence increases, there is a notable shift towards precision medicine, positioning ADCs as a key treatment approach. Enhanced investments in R&D by biopharma and biotech firms are anticipated to further propel market expansion. Additionally, the complexity of ADC manufacturing processes-necessitating specialized bioconjugation techniques and advanced testing methods-opens up new business opportunities. Meanwhile, regulatory support for innovative ADC therapies through expedited approvals is expected to elevate demand for contract manufacturing services. However, challenges such as high production costs, stringent regulations, limited specialized manufacturers, and supply chain issues may restrict market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Drug Conjugates Contract Manufacturing Market Segments Analysis

Global Antibody Drug Conjugates Contract Manufacturing Market is segmented by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User and region. Based on Stage of Development, the market is segmented into Phase I, Phase II and Phase III. Based on Process Component, the market is segmented into Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker and Fill / Finish. Based on Target Indication, the market is segmented into Solid Tumors, Hematological Tumors and Others. Based on Antibody Generation, the market is segmented into Second Generation, Third Generation, Fourth Generation and Next Generation. Based on Antibody Origin, the market is segmented into Humanized, Chimeric, Murine and Others. Based on Type of Linker, the market is segmented into Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline and Others. Based on End User, the market is segmented into Pharmaceutical Companies, Biotechnology Companies - 30%, Academic & Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Drug Conjugates Contract Manufacturing Market

The expanding therapeutic applications of various antibody drug conjugates have spurred significant investments in research and development from numerous pharmaceutical and biotechnology firms. As clinical trials advance, the demand for manufacturing partners that can provide scalable and compliant production capabilities has intensified. Furthermore, the rising approvals of antibody drug conjugates globally are anticipated to generate fresh opportunities for companies specializing in contract manufacturing of these innovative therapies. This dynamic landscape underscores the growing importance of outsourcing manufacturing services in order to meet the evolving needs of the antibody drug conjugate market.

Restraints in the Global Antibody Drug Conjugates Contract Manufacturing Market

The global market for antibody drug conjugates contract manufacturing faces notable constraints due to the complexity of its design, development, and production processes. This manufacturing requires specialized facilities dedicated to antibody production, the handling of cytotoxic drugs, and the conjugation process, which demands substantial capital investment. Additionally, the high costs associated with research and development, driven by extensive preclinical and clinical testing necessary to verify safety and efficacy, are likely to hinder demand for contract manufacturing services in this field over time. These factors collectively create significant challenges for stakeholders involved in the market.

Market Trends of the Global Antibody Drug Conjugates Contract Manufacturing Market

The Global Antibody Drug Conjugates Contract Manufacturing market is witnessing a significant trend driven by strategic collaborations and capacity expansions among key players. To enhance operational efficiency and mitigate potential supply chain disruptions, companies are increasingly partnering with pharmaceutical innovators, securing dedicated manufacturing slots that streamline production processes. This focus on collaboration not only addresses bottlenecks but also underlines a growing demand for adaptable manufacturing solutions. As healthcare continues to evolve, the emphasis on scalability and flexibility positions this market trend as a cornerstone of sustained growth, facilitating the delivery of advanced therapeutics to meet rising global demand.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Raw Material Analysis

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Stage of Development & CAGR (2026-2033)

• Market Overview
• Phase I
• Phase II
• Phase III

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Process Component & CAGR (2026-2033)

• Market Overview
• Antibody
• HPAPI / Cytotoxic Payload
• Conjugation / Linker
• Fill / Finish

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Target Indication & CAGR (2026-2033)

• Market Overview
• Solid Tumors
• Hematological Tumors
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Antibody Generation & CAGR (2026-2033)

• Market Overview
• Second Generation
• Third Generation
• Fourth Generation
• Next Generation

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Antibody Origin & CAGR (2026-2033)

• Market Overview
• Humanized
• Chimeric
• Murine
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Type of Linker & CAGR (2026-2033)

• Market Overview
• Maleimide
• SMCC
• Tetrapeptide-based linker
• Valine-citrulline
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies - 30%
• Academic & Research Institutes
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size & CAGR (2026-2033)

• North America (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • US
  • Canada
• Europe (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi XDC (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Pharma Solutions (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MilliporeSigma (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sterling Pharma Solutions (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cerbios-Pharma SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CARBOGEN AMCIS (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abzena PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (Cayman Islands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ajinomoto Bio-Pharma Services (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axplora (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Contract Manufacturing (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Formosa Laboratories (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veranova (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations